• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

毒理学和辐射对策研究中相对效力的区间估计:方法与实验设计比较

Interval estimators of relative potency in toxicology and radiation countermeasure studies: comparing methods and experimental designs.

作者信息

Landes Reid D, Lensing Shelly Y, Hauer-Jensen Martin

机构信息

a Department of Biostatistics , University of Arkansas for Medical Sciences , Little Rock , Arkansas , USA.

b Division of Radiation Health , University of Arkansas for Medical Sciences, and Central Arkansas Veterans Healthcare System , Little Rock , Arkansas , USA.

出版信息

J Biopharm Stat. 2019;29(2):348-358. doi: 10.1080/10543406.2018.1535500. Epub 2018 Oct 23.

DOI:10.1080/10543406.2018.1535500
PMID:30352015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6450382/
Abstract

The relative potency of one agent to another is commonly represented by the ratio of two quantal response parameters; for example, the LD of animals receiving a treatment to the LD of control animals, where LD is the dose of toxin that is lethal to 50% of animals. Though others have considered interval estimators of LD, here, we extend Bayesian, bootstrap, likelihood ratio, Fieller's and Wald's methods to estimate intervals for relative potency in a parallel-line assay context. In addition to comparing their coverage probabilities, we also consider their power in two types of dose designs: one assigning treatment and control the same doses vs. one choosing doses for treatment and control to achieve same lethality targets. We explore these methods in realistic contexts of relative potency of radiation countermeasures. For larger experiments (e.g., ≥100 animals), the methods return similar results regardless of the interval estimation method or experiment design. For smaller experiments (e.g., < 60 animals), Wald's method stands out among the others, producing intervals that hold closely to nominal levels and providing more power than the other methods in statistically efficient designs. Using this simple statistical method within a statistically efficient design, researchers can reduce animal numbers.

摘要

一种药剂相对于另一种药剂的相对效力通常由两个质反应参数的比值表示;例如,接受治疗的动物的半数致死量(LD)与对照动物的半数致死量之比,其中LD是对50%的动物致死的毒素剂量。尽管其他人已经考虑了LD的区间估计,但在这里,我们扩展了贝叶斯、自助法、似然比、菲勒法和沃尔德法,以估计平行线试验背景下相对效力的区间。除了比较它们的覆盖概率,我们还考虑它们在两种剂量设计中的功效:一种是给治疗组和对照组分配相同的剂量,另一种是为治疗组和对照组选择剂量以达到相同的致死率目标。我们在辐射防护措施相对效力的实际背景下探索这些方法。对于较大规模的实验(例如,≥100只动物),无论采用哪种区间估计方法或实验设计,这些方法都会得出相似的结果。对于较小规模的实验(例如,<60只动物),沃尔德法在其他方法中脱颖而出,产生的区间与名义水平紧密相符,并且在统计效率高的设计中比其他方法具有更高的功效。在统计效率高的设计中使用这种简单的统计方法,研究人员可以减少动物数量。

相似文献

1
Interval estimators of relative potency in toxicology and radiation countermeasure studies: comparing methods and experimental designs.毒理学和辐射对策研究中相对效力的区间估计:方法与实验设计比较
J Biopharm Stat. 2019;29(2):348-358. doi: 10.1080/10543406.2018.1535500. Epub 2018 Oct 23.
2
Interval estimation of generalized odds ratio in data with repeated measurements.具有重复测量数据中广义优势比的区间估计。
Stat Med. 2002 Oct 30;21(20):3107-17. doi: 10.1002/sim.1239.
3
Eight interval estimators of a common rate ratio under stratified Poisson sampling.分层泊松抽样下共同率比的八个区间估计量。
Stat Med. 2004 Apr 30;23(8):1283-96. doi: 10.1002/sim.1725.
4
Interval estimation of risk ratio in the simple compliance randomized trial.简单依从性随机试验中风险比的区间估计。
Contemp Clin Trials. 2007 Feb;28(2):120-9. doi: 10.1016/j.cct.2006.05.005. Epub 2006 Jul 3.
5
Practical advice on calculating confidence intervals for radioprotection effects and reducing animal numbers in radiation countermeasure experiments.辐射防护效果置信区间计算和减少辐射防护对策实验动物数量的实用建议。
Radiat Res. 2013 Dec;180(6):567-74. doi: 10.1667/RR13429.1. Epub 2013 Oct 28.
6
An alternative approach to the optimal design of an LD50 bioassay.
Stat Med. 1995 Apr 30;14(8):841-52. doi: 10.1002/sim.4780140812.
7
A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.用于估计连续终点基准剂量的毒性研究设计的统计评估。
Toxicol Sci. 2005 Mar;84(1):167-85. doi: 10.1093/toxsci/kfi004. Epub 2004 Oct 13.
8
Interval estimation of the risk ratio between a secondary infection, given a primary infection, and the primary infection.给定初次感染情况下二次感染与初次感染之间风险比的区间估计。
Biometrics. 1998 Jun;54(2):706-11.
9
Notes on interval estimation of the attributable risk in cross-sectional sampling.横断面抽样中归因风险区间估计的注释
Stat Med. 2001 Jun 30;20(12):1797-809. doi: 10.1002/sim.777.
10
Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.使用聚类定性数据对基准剂量和置信限进行自助法估计。
Risk Anal. 2007 Apr;27(2):447-65. doi: 10.1111/j.1539-6924.2007.00897.x.

引用本文的文献

1
Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications.使用世界卫生组织国际标准品(NIBSC 20/136)对多种严重急性呼吸综合征冠状病毒2参考物质进行校准:结果与影响
Front Microbiol. 2022 May 30;13:893801. doi: 10.3389/fmicb.2022.893801. eCollection 2022.

本文引用的文献

1
Practical advice on calculating confidence intervals for radioprotection effects and reducing animal numbers in radiation countermeasure experiments.辐射防护效果置信区间计算和减少辐射防护对策实验动物数量的实用建议。
Radiat Res. 2013 Dec;180(6):567-74. doi: 10.1667/RR13429.1. Epub 2013 Oct 28.
2
Determination of sample sizes for demonstrating efficacy of radiation countermeasures.确定用于证明辐射防护措施有效性的样本量。
Biometrics. 2010 Mar;66(1):239-48. doi: 10.1111/j.1541-0420.2009.01236.x. Epub 2009 May 7.
3
Estimation of cancer drug potencies and relative potencies from in vitro data.根据体外实验数据估算抗癌药物的效力和相对效力。
J Biopharm Stat. 2005;15(6):903-12. doi: 10.1080/10543400500265595.
4
Statistical inference for relative potency in bivariate dose-response assays with correlated responses.
J Biopharm Stat. 2005;15(2):343-51. doi: 10.1081/BIP-200048798.
5
Confidence intervals for the 50 per cent response dose.50%反应剂量的置信区间。
Stat Med. 2003 Jun 30;22(12):1977-88. doi: 10.1002/sim.1368.
6
New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.新药和生物制品;在人体有效性研究不符合伦理或不可行时证明新药有效性所需的证据。最终规则。
Fed Regist. 2002 May 31;67(105):37988-98.
7
Interval estimation of the median lethal dose.半数致死剂量的区间估计。
Biometrics. 1986 Sep;42(3):641-5.